Massacesi Cristian 4

What Happened

• Cristian Massacesi, EVP, Chief Medical Officer and Head of Development at Bristol Myers Squibb (BMY), was granted two derivative awards on 2026-03-10 totaling 65,306 units (26,122 and 39,184). Each award was recorded at $0.00 per share because these are performance- and market-linked unit awards, not open-market purchases or cash transactions. No immediate cash changed hands.

Key Details

• Transaction date: 2026-03-10; Form 4 filed 2026-03-12 (filed two days after the grant).
• Grant amounts: 26,122 units and 39,184 units (total 65,306 units); price per unit reported $0.00 (derivative awards).
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes (summary):
  • Market share units use a payout factor based on Total Return or relative TSR (rTSR) with minimum Total Return payout at 80% and max 225%; rTSR below 50th percentile yields 0% payout, 50th–74.99th = 50%, ≥75th = 100%.
  • Market share units cliff vest on the third anniversary of the grant, subject to Board certification.
  • Performance share units convert to common stock upon distribution in Q1 2029, subject to Board certification.
• Remark: Exhibit 24 (Power of Attorney) attached to the filing.

Context

• These are long-term incentive awards tied to company performance and timing, not immediate stock purchases or sales. Their ultimate value depends on future stock price and relative/absolute performance metrics and Board certification of results. Retail investors should view this as compensation-related equity grants rather than a direct buy/sell signal.